{"id":5974,"date":"2022-06-26T08:13:23","date_gmt":"2022-06-26T02:43:23","guid":{"rendered":"http:\/\/induspharma.in\/?p=5974"},"modified":"2022-12-29T11:16:10","modified_gmt":"2022-12-29T05:46:10","slug":"cisatracurium-besylate-injection","status":"publish","type":"post","link":"https:\/\/induspharma.in\/productslist\/cisatracurium-besylate-injection\/","title":{"rendered":"Cisatracurium Besylate Injection"},"content":{"rendered":"<p>COMPOSITION<br>\nEach ml contains:<br>\nCisatracurium Besylate USP<br>\nEq. to Cisatracurium 2mg<br>\nBenzyl Alcohol USP 0.9%<br>\n(As preservative in Multi dose Vial)<br>\nWater for Injection USP q.s.<br>\nCLINICAL PHARMACOLOGY<br>\nPharmacodynamic properties<br>\nPharmacotherapeutic group: Neuromuscular blocking agent<br>\nATC code: M03AC11<br>\nCisatracurium is an intermediate-duration, non-depolarising benzylisoquinolinium skeletal<br>\nmuscle relaxant.<br>\nClinical studies in man indicated that cisatracurium is not associated with dose dependent<br>\nhistamine release even at doses up to and including 8 x ED95.<br>\nMechanism of action<br>\nCisatracurium binds to cholinergic receptors on the motor end-plate to antagonise the action of<br>\nacetylcholine, resulting in a competitive block of neuromuscular transmission. This action is<br>\nreadily reversed by anti-cholinesterase agents such as neostigmine or edrophonium.<br>\nThe ED95 (dose required to produce 95% depression of the twitch response of the adductor<br>\npollicis muscle to stimulation of the ulnar nerve) of cisatracurium is estimated to be 0.05 mg\/kg<br>\nbodyweight during opioid anaesthesia (thiopentone\/fentanyl\/midazolam).<br>\nThe ED95 of cisatracurium in children during halothane anaesthesia is 0.04 mg\/kg.<\/p>\n<hr>\n<a href=\"https:\/\/induspharma.in\/productslist\/wp-content\/uploads\/2022\/06\/Cisatracurium-Besylate-Injection-USP-2mgml.pdf\" class=\"pdfemb-viewer\" style=\"\" data-width=\"max\" data-height=\"max\" data-toolbar=\"both\" data-toolbar-fixed=\"on\">Cisatracurium Besylate Injection USP 2mgml<\/a>\n","protected":false},"excerpt":{"rendered":"<p>COMPOSITION Each ml contains: Cisatracurium Besylate USP Eq. to Cisatracurium 2mg Benzyl Alcohol USP 0.9% (As preservative in Multi dose Vial) Water for Injection USP q.s. CLINICAL PHARMACOLOGY Pharmacodynamic properties Pharmacotherapeutic group: Neuromuscular blocking agent ATC code: M03AC11 Cisatracurium is an intermediate-duration, non-depolarising benzylisoquinolinium skeletal muscle relaxant. Clinical studies in man indicated that cisatracurium is&#8230;<\/p>\n","protected":false},"author":1,"featured_media":6345,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/posts\/5974"}],"collection":[{"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/comments?post=5974"}],"version-history":[{"count":4,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/posts\/5974\/revisions"}],"predecessor-version":[{"id":6433,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/posts\/5974\/revisions\/6433"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/media\/6345"}],"wp:attachment":[{"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/media?parent=5974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/categories?post=5974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/tags?post=5974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}